Patents by Inventor Jianmei Wu Leavenworth

Jianmei Wu Leavenworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20230302106
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: February 27, 2023
    Publication date: September 28, 2023
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
    Patent number: 11590213
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 28, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
    Patent number: 11371989
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 28, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20210268081
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: December 18, 2019
    Publication date: September 2, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20200297828
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: December 18, 2019
    Publication date: September 24, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
    Patent number: 10548957
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: February 4, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS
    Publication number: 20190178884
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Application
    Filed: November 19, 2018
    Publication date: June 13, 2019
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS
    Publication number: 20170269076
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Application
    Filed: August 27, 2015
    Publication date: September 21, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20150250862
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 10, 2015
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth